EDLS-401

EDLS-401 is a preclinical-stage drug delivery program developed by Edulis Therapeutics for the treatment of weight loss. The system utilizes a proprietary endoscopic delivery platform consisting of a bioresorbable polymer matrix implant, which is thinner than a grain of rice. Once endoscopically placed in the gastrointestinal tract, the implant provides sustained local or systemic delivery of a small-molecule therapeutic for up to 12 months. This approach is designed to improve bioavailability and patient compliance compared to traditional oral formulations. While the specific molecular target of the small molecule within EDLS-401 has not been disclosed, the platform aims to optimize therapeutic management of metabolic conditions.